AstraZeneca Surges As It Takes A Shot At Gilead ' s Second-Biggest Cancer Drug

and Daiichi Sankyo said Friday their breast cancer treatment outperformed chemotherapy in a Phase 3 study, and AZN stock jumped to its 50-day line. The companies are in the antibody drug conjugate, or ADC, space with a medicine called datopotamab deruxteca. ADCs are like smart bombs, targeting…#daiichisankyo #azn #astrazeneca #adc #marketsmithcom #trodelvy #gileadsciences #gild #isi #umerraffat
Source: Reuters: Health - Category: Consumer Health News Source Type: news